Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RXRX by emailGet an email when RXRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RXRX, unsubscribe in one click. Privacy
📣 What RXRX Says Is Next
1H27 · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27”
Company press release, Aug 5, 2026 · SEC filing
1H27 · “REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27”
Company press release, Aug 5, 2026 · SEC filing
2H26 · “REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RXRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RXRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.